Adaptive Biotechnologies (NASDAQ: ADPT) reported Q3 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $46.4 million versus the consensus estimate of $40.21 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2024 revenue of $143-145 million, versus the consensus of $172.1 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.